Panobinostat shows efficacy in Hodgkin lymphoma.
Panobinostat monotherapy is active against relapsed or refractory Hodgkin lymphoma.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D008297:Male
D000970:Antineoplastic Agents; D006877:Hydroxamic Acids